



Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer

Alessia Lena, MD,^{a,b,c,d} Ursula Wilkenshoff, MD,^{a,b,e} Sara Hadzibegovic, MD,^{a,b,c,d} Jan Porthun, MMSc,^{b,f,g} Lukas Rösnick,^{b,c,d,f} Ann-Kathrin Fröhlich,^{b,c,d,f} Tanja Zeller, PhD,^{h,i,j} Mahir Karakas, MD, PhD, MBA,^{j,k} Ulrich Keller, MD,^{l,m,n} Johann Ahn, MD,^o Lars Bullinger, MD,^{m,o} Hanno Riess, MD,^p Stuart D. Rosen, MD,^{q,r,s} Alexander R. Lyon, MD, PhD,^q Thomas F. Lüscher, MD,^{q,r,s,t} Matthias Totzeck, MD,^u Tienush Rassaf, MD,^u Daniel Burkhoff, MD, PhD,^v Mandeep R. Mehra, MD, MSc,^w Jeroen J. Bax, MD, PhD,^{x,y} Javed Butler, MD, MPH, MBA,^{z,aa} Frank Edelmann, MD,^{b,c,e,f} Wilhelm Haverkamp, MD,^{c,d,bb} Stefan D. Anker, MD, PhD,^{c,d,bb} Milton Packer, MD,^{cc} Andrew J.S. Coats, DM, DSc, MBA,^{dd} Stephan von Haehling, MD, PhD,^{ee,ff} Ulf Landmesser, MD,^{a,b,c,e} Markus S. Anker, MD^{a,b,c,d}

ABSTRACT

BACKGROUND Body wasting in patients with cancer can affect the heart.

OBJECTIVES The frequency, extent, and clinical and prognostic importance of cardiac wasting in cancer patients is unknown.

METHODS This study prospectively enrolled 300 patients with mostly advanced, active cancer but without significant cardiovascular disease or infection. These patients were compared with 60 healthy control subjects and 60 patients with chronic heart failure (ejection fraction <40%) of similar age and sex distribution.

RESULTS Cancer patients presented with lower left ventricular (LV) mass than healthy control subjects or heart failure patients (assessed by transthoracic echocardiography: 177 ± 47 g vs 203 ± 64 g vs 300 ± 71 g, respectively; $P < 0.001$). LV mass was lowest in cancer patients with cachexia (153 ± 42 g; $P < 0.001$). Importantly, the presence of low LV mass was independent of previous cardiotoxic anticancer therapy. In 90 cancer patients with a second echocardiogram after 122 ± 71 days, LV mass had declined by $9.3\% \pm 1.4\%$ ($P < 0.001$). In cancer patients with cardiac wasting during follow-up, stroke volume decreased ($P < 0.001$) and resting heart rate increased over time ($P = 0.001$). During follow-up of on average 16 months, 149 patients died (1-year all-cause mortality 43%; 95% CI: 37%-49%). LV mass and LV mass adjusted for height squared were independent prognostic markers (both $P < 0.05$). Adjustment of LV mass for body surface area masked the observed survival impact. LV mass below the prognostically relevant cutpoints in cancer was associated with reduced overall functional status and lower physical performance.

CONCLUSIONS Low LV mass is associated with poor functional status and increased all-cause mortality in cancer. These findings provide clinical evidence of cardiac wasting-associated cardiomyopathy in cancer.

(J Am Coll Cardiol 2023;81:1569-1586) © 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Listen to this manuscript's
audio summary by
Editor-in-Chief
Dr Valentin Fuster on
www.jacc.org/journal/jacc.

From the ^aDepartment of Cardiology, Angiology and Intensive Care Medicine Campus Benjamin Franklin, German Heart Center Charité, Berlin, Germany; ^bCharité - University Medicine Berlin, corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany; ^cGerman Centre for Cardiovascular Research, partner site Berlin, Berlin, Germany; ^dBerlin Institute of Health Center for Regenerative Therapies, Berlin, Germany; ^eBerlin Institute of Health, Charité - University Medicine Berlin, Berlin, Germany; ^fDepartment of Cardiology, Angiology and Intensive Care Medicine Campus Virchow Clinic, German Heart Center Charité, Berlin, Germany; ^gNorwegian University of Science and Technology, Campus Gjøvik, Gjøvik, Norway; ^hUniversity Center of Cardiovascular Science, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; ⁱClinic for Cardiology, University Heart and Vascular Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; ^jGerman Centre for Cardiovascular Research, partner site HH/Kiel/HL, Hamburg, Germany; ^kDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ^lDepartment of Hematology, Oncology and

ABBREVIATIONS AND ACRONYMS

BSA = body surface area

CRP = C-reactive protein

ECOG = Eastern Cooperative
Oncology Group

IL = interleukin

IVSd = interventricular septal
thickness at end-diastole

LV = left ventricular

LVEF = left ventricular ejection
fraction

LVIDd = left ventricular
internal diameter at end-
diastole

PWd = posterior wall thickness
at end-diastole

TNF = tumor necrosis factor

T2DM = type 2 diabetes
mellitus

In advanced cancer, cachexia is frequently observed in 30% to 80% of patients, depending on the cancer type, stage, and comorbidities.^{1,2} Cachexia is characterized by involuntary weight loss associated with loss of both skeletal muscle mass and fat tissue.³ Other symptoms, such as fatigue, impaired physical performance, and dyspnea, are associated with cancer cachexia.⁴ These symptoms are also frequently observed in chronic heart failure. There are multiple possible reasons for whole body wasting in cancer, including chronic and systemic inflammation (ie, cytokine mediated), neurohormonal alterations, metabolic dysregulation, and mitochondrial dysfunction.^{5,6} All these pathophysiologic abnormalities may also affect the heart in cancer patients. In experimental models of cancer, cardiac wasting has been repeatedly observed,^{7,8} and 1 study also documented this condition as a late-stage phenomenon in a rat cancer model with clinical features of advanced heart failure.⁹ In human cancer patients, reductions of left ventricular (LV) mass have been described in 3 preliminary studies.^{9–11}

SEE PAGE 1587

We previously proposed that cancer patients with advanced-stage disease develop *cardiac wasting-associated cardiomyopathy*.⁴ Tumor-related wasting processes may cause many different structural and hemodynamic alterations in the cardiac milieu resulting in arrhythmias and clinical heart failure.^{4,12} We hypothesized that cardiac wasting mainly occurs in advanced stages of different cancer types, and it is

enhanced by generalized body wasting and independent of systemic anticancer therapy (cardiotoxic or noncardiotoxic). Furthermore, we hypothesized that cardiac wasting may be associated with reduced functional outcomes and prognosis. From a methodologic point of view, LV mass adjustment for body surface area (BSA), which is currently the common mean for standardization,¹³ may be misleading in advanced-stage cancer patients when assessing them for LV muscle wasting. Indeed, adjustment of LV mass for BSA may mask cardiac wasting, particularly when body weight is significantly reduced, which also reduces BSA values and results in small or no detectable changes of LV mass adjusted for BSA.

We hypothesized that LV mass adjustment for the square of the patients' height or unadjusted data should be used in patients with advanced-stage cancer instead of adjustment for BSA. Although BSA adjustment is needed in children, it is arguable whether it is needed in any other situations. For example, one could argue that BSA adjustment is also not needed in the evaluation of obesity-related heart failure, which could be considered the opposite problem of "cachexia-related heart failure" with regard to LV mass and its adjustment for frame size. We have designed this study to prospectively investigate the best metric(s) for quantifying cardiac wasting in patients with advanced-stage cancer, its pathophysiologic correlates, and prognostic implications.

METHODS

PATIENT GROUP. Between September 2017 and October 2020, we prospectively examined 320 hospitalized cancer patients admitted to the oncology department of the Charité-Berlin University of

Cancer Immunology, Charité - University Medicine Berlin, Campus Benjamin-Franklin, Berlin, Germany; ^mGerman Cancer Research Center and German Cancer Consortium, Heidelberg, Germany; ⁿMax Delbrück Center, Berlin, Germany; ^oDepartment of Hematology, Oncology, and Tumor Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany; ^pDepartment of Hematology, Oncology, and Tumor Immunology, Charité - University Medicine Berlin, Campus CCM, Berlin, Germany; ^qCardio-Oncology Service, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, United Kingdom; ^rHeart Division, Royal Brompton & Harefield Hospitals, London, United Kingdom; ^sNational Heart and Lung Institute, Imperial College London, London, United Kingdom; ^tCenter for Molecular Cardiology, University of Zurich, Zurich, Switzerland; ^uDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany; ^vCardiovascular Research Foundation, New York, New York, USA; ^wBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, USA; ^xDepartment of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; ^yTurku University, Turku, Finland; ^zBaylor Scott and White Research Institute, Dallas, Texas, USA; ^{aa}University of Mississippi, Jackson, Mississippi, USA; ^{bb}Department of Cardiology Campus Virchow Clinic of German Heart Center Charité, Charité - University Medicine Berlin, Berlin, Germany; ^{cc}Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA; ^{dd}Heart Research Institute, Sydney, New South Wales, Australia; ^{ee}Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany; and the ^{ff}German Centre for Cardiovascular Research, partner site Göttingen, Göttingen, Germany. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

TABLE 1 Baseline Characteristics

	Healthy Control Subjects (n = 60)	All Cancer Patients (n = 300)	Heart Failure Patients (n = 60)	ANOVA P Value ^a	Cachectic Cancer Patients (n = 87)	Noncachectic Cancer Patients (n = 213)	ANOVA P Value ^b
Clinical parameters							
Age, y	60 ± 8	62 ± 14	62 ± 11	0.40	63 ± 14	62 ± 14	0.54
Female	36 (60)	154 (51)	28 (47)	0.22	47 (54)	107 (50)	0.45
BMI, kg/m ²	25.7 ± 3.8	24.8 ± 4.9 ^c	27.8 ± 5.3 ^d	<0.001	20.5 ± 2.4 ^{c,e,f}	26.6 ± 4.6 ^g	<0.001
Systolic BP, mm Hg	137 ± 17	128 ± 19 ^{c,h}	117 ± 19 ^f	<0.001	121 ± 17 ^{e,f}	131 ± 19 ^{c,d}	<0.001
Diastolic BP, mm Hg	87 ± 10	78 ± 12 ^{f,g}	74 ± 13 ^f	<0.001	76 ± 12 ^{f,i}	79 ± 11 ^{c,f}	<0.001
Dyspnea under exertion	3 (5)	146 (49) ^f	35 (58) ^f	<0.001	48 (55) ^f	98 (46) ^f	<0.001
Cancer and anticancer therapy details							
Cancer stage III/IV	—	241 (80)	—	—	77 (89)	164 (77)	0.020
Solid cancer	—	159 (53)	—	—	58 (67)	101 (47)	0.002
ECOG performance scale ≥3	—	81 (28)	—	—	40 (46)	41 (19)	<0.001
First therapy line of anticancer therapy	—	95 (32)	—	—	28 (32)	67 (32)	0.90
Previous cardiotoxic anticancer therapy	—	125 (42)	—	—	43 (49)	82 (39)	0.081
Anticancer therapy naive	—	96 (32)	—	—	20 (23)	76 (36)	0.032
Side diagnosis							
Anemia	9 (15)	251 (84) ^{c,f}	33 (55) ^f	<0.001	85 (98) ^{c,e,f}	166 (78) ^{c,f}	<0.001
Arterial hypertension	25 (42)	133 (45) ^c	47 (78) ^f	<0.001	30 (35) ^{c,i}	103 (49) ^c	<0.001
Hypercholesterolemia	38 (63)	96 (32) ^{f,j}	32 (53)	<0.001	16 (18) ^{c,f,k}	80 (38) ^{f,d}	<0.001
Type 2 diabetes mellitus	1 (2)	40 (14) ^{h,j}	18 (30) ^f	<0.001	7 (8) ^c	33 (16) ^{g,h}	<0.001
Chronic kidney disease	0 (0)	24 (8) ^{c,d}	18 (30) ^f	<0.001	8 (9) ^{h,j}	16 (8) ^{c,d}	<0.001
Laboratory parameters							
Sodium, mmol/L	141 ± 2	139 ± 4 ^{f,g}	140 ± 3	<0.001	138 ± 4 ^{f,i}	139 ± 4 ^f	<0.001
Potassium, mmol/L	4.1 ± 0.3	3.8 ± 0.4 ^{c,f}	4.3 ± 0.4 ^h	<0.001	3.9 ± 0.5 ^{c,h}	3.8 ± 0.4 ^{c,f}	<0.001
Hemoglobin, g/dL	14.4 ± 1.1	11.1 ± 2.2 ^{c,f}	13.3 ± 2.0 ^h	<0.001	10.2 ± 1.8 ^{c,e,f}	11.5 ± 2.2 ^{c,f}	<0.001
Leukocytes, /nL	6.1 ± 1.9	8.1 ± 6.6 ^d	8.6 ± 2.5	0.033	7.9 ± 6.7	8.2 ± 6.6	0.07
Platelets, /nL	251 ± 55	250 ± 131	256 ± 79	0.94	249 ± 145	250 ± 126	0.99
eGFR, mL/min/1.73 m ²	86 ± 11	86 ± 23 ^c	63 ± 23 ^f	<0.001	86 ± 26 ^c	87 ± 22 ^c	<0.001
LDL, mg/dL	138 ± 36	106 ± 40 ^{f,i}	98 ± 9 ^f	<0.001	95 ± 42 ^{f,k}	111 ± 39 ^{c,f}	<0.001
GOT, U/L	26 (22-28)	26 (21-40)	30 (21-39)	0.12	26 (19-48)	26 (22-37)	0.23
Hs troponin T, ng/L	5 (3-8)	11 (7-21) ^{c,f}	22 (12-45) ^f	<0.001	14 (8-26) ^f	11 (6-17) ^{c,f}	<0.001
NT-proBNP, ng/L	59 (42-143)	281 (118-621) ^{c,f}	1,548 (572-8,179) ^f	<0.001	351 (169-742) ^{c,f}	244 (99-559) ^{c,f}	<0.001
CRP, mg/L	1 (1-3)	10 (3-33) ^{f,g}	4 (1-16) ^f	<0.001	16 (3-50) ^{f,i}	8 (3-26) ^f	<0.001
Interleukin-6, pg/mL	2.5 (1.6-3.3)	9.0 (4.0-23.3)	—	<0.001	19.0 (5.6-38.6) ^{f,k}	6.9 (3.2-18.4) ^f	<0.001
Interleukin-18, pg/mL	0 (0.0-0.1)	0.07 (0.0-0.18)	—	<0.001	0.12 (0.0-0.26) ^{f,i}	0.055 (0.00-0.16) ^h	<0.001
Interleukin-10, pg/mL	0.018 (0.010-0.479)	0.396 (0.010-1.261)	—	<0.001	0.353 (0.010-1.23) ^f	0.396 (0.010-1.267) ^f	0.001
TNF, pg/mL	1.19 (1.04-1.35)	1.94 (1.33-2.99)	—	<0.001	1.94 (1.40-2.92) ^f	1.95 (1.32-3.25) ^f	<0.001
Medications							
ACE inhibitors/ARBs	13 (22)	77 (26) ^c	31 (52) ^f	<0.001	17 (20) ^c	60 (28) ^h	<0.001
ARNi	0 (0)	0 (0) ^c	29 (48) ^f	<0.001	0 (0) ^c	0 (0) ^c	<0.001
Beta-blockers	2 (3)	55 (18) ^{c,h}	57 (95) ^f	<0.001	13 (15) ^{c,d}	42 (20) ^{c,h}	<0.001
Anticoagulant agents	1 (2)	11 (4) ^c	20 (33) ^f	<0.001	2 (2) ^c	9 (4) ^c	<0.001
Diuretic agents	2 (3)	54 (18) ^{c,h}	49 (82) ^f	<0.001	11 (13) ^c	43 (20) ^{c,h}	<0.001
Antidepressants	1 (2)	41 (14) ^h	5 (8)	0.011	12 (14) ^d	29 (14) ^h	0.027
Opioids	0 (0)	66 (22) ^{c,f}	1 (2)	<0.001	26 (30) ^{c,f,i}	40 (19) ^{c,f}	<0.001
Corticosteroids	0 (0)	99 (33) ^{c,f}	4 (7)	<0.001	22 (25) ^{c,f}	77 (36) ^{c,f}	<0.001

Values are mean ± SD, n (%), or median (IQR). P values for nominal variables refer to all comparison groups. ^aANOVA P value/chi-square test for comparisons among cancer patients, healthy control subjects, and heart failure patients. ^bANOVA P value/chi-square test for comparisons among cachectic cancer patients, noncachectic cancer patients, healthy control subjects, and heart failure patients. ^cP <0.001 vs heart failure patients. ^dP <0.05 vs control subjects. ^eP <0.001 vs noncachectic cancer patients. ^fP <0.001 vs control subjects. ^gP <0.05 vs heart failure patients. ^hP <0.01 vs control subjects; ⁱP <0.05 vs noncachectic cancer patients. ^jP <0.01 vs heart failure patients. ^kP <0.01 vs noncachectic cancer patients.

ACE = angiotensin-converting enzyme; ANOVA = analysis of variance; ARB = angiotensin II receptor blocker; ARNi = angiotensin receptor-neprilysin inhibitor; BMI = body mass index; BP = blood pressure; BSA = body surface area; CRP = C-reactive protein; ECOG = Eastern Cooperative Oncology Group; eGFR = estimated glomerular filtration rate; GOT = glutamic-oxaloacetic transaminase; hs = high-sensitivity; LDL = low-density lipoprotein; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TNF = tumor necrosis factor.

Medicine in Berlin, Germany. To be eligible for our study, all cancer patients needed the following: histologically proven, active cancer; age ≥ 18 years; willingness and ability to participate in a prospective study; and ability to sign the informed consent form themselves. Exclusion criteria for our study were as follows: 1) a different cancer diagnosis in the 5 years before study inclusion; 2) clinical signs of an acute infection or active antibiotic therapy; 3) a history or presence of significant cardiovascular disease (eg, coronary artery disease, myocardial infarction, severe cardiac valve dysfunction, or LV ejection fraction [LVEF] $< 50\%$); or 4) the presence of severe chronic obstructive pulmonary disease at Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage $> II^{14}$ (all GOLD stages were allowed in lung cancer). Patients with type 2 diabetes mellitus (T2DM) without cardiovascular complications and controlled arterial hypertension with blood pressure $< 160/100$ mm Hg were not excluded. Cancer patients were allowed to be anticancer therapy naive or to have received cardiotoxic or noncardiotoxic anticancer therapy previously. Of the 320 cancer patients who were included in the study, 6 patients were excluded because of newly diagnosed LVEF $< 50\%$ (according to the exclusion criteria of the study), and 14 cancer patients were excluded for insufficient echocardiographic images for LV mass calculations. The final study cohort comprised 300 cancer patients. Main reasons for hospitalization were as follows: systemic anticancer therapy administration ($n = 123$); diagnostic examinations ($n = 102$); worsening clinical condition ($n = 38$); pain exacerbation ($n = 13$); shortness of breath ($n = 12$); and neurologic symptoms ($n = 12$).

Sixty healthy control subjects of similar sex and age distribution were recruited. Healthy control subjects were free of significant cardiovascular disease and were generally healthy. T2DM and controlled arterial hypertension were not exclusion criteria.

For additional comparison, we also analyzed a control group of 60 patients from our hospital records with chronic heart failure and reduced ejection fraction (all with LVEF $< 40\%$) according to the current guidelines of the European Society of Cardiology,¹⁵ as well as available blood biomarkers and a well-documented echocardiogram in our departments' records. All heart failure patients were investigated in the same time span as the cancer patients, and they had similar sex and age distribution as the cancer patients.

STUDY DESIGN. All cancer patients and healthy control subjects were prospectively examined. All patients underwent the following: a detailed medical

history; physical examination, including determination of body weight, height, and BSA; blood samples for biomarker analyses; and a 12-lead resting electrocardiogram. For patient-reported outcomes and functional assessment, we used several instruments: the Eastern Cooperative Oncology Group (ECOG) performance scale,¹⁶ the Karnofsky Index performance status,¹⁷ EQ-5D-5L questionnaire,¹⁸ the Visual Analogue Scale for appetite¹⁹ and pain,²⁰; and the Mini Nutritional Assessment.²¹ The following functional assessment tests were all performed according to the respective standard protocols: maximum handgrip strength²²; 4-meter gait speed²³; 10-step stair-climbing power test²⁴; and 6-minute walk test.²⁵

All cancer patients were offered an echocardiographic follow-up examination within the first 12 months after study recruitment, but we aimed to conduct this examination within the first 6 months. Cancer patients were grouped by the presence of cachexia at baseline and were compared with healthy control subjects and patients with chronic heart failure. Cachexia was diagnosed when weight loss was $\geq 5\%$ in the previous 12 months as reported by the patients and body mass index was < 24.0 kg/m² at baseline (adapted from Fearon et al,²⁶ as well as recent clinical trials²⁷). Advanced-stage cancer was defined as any of the following: stage III/IV, Union for International Cancer Control²⁸; stage III/IV, Ann Arbor classification²⁹; and stage III, Durie and Salmon classification.³⁰ Cardiotoxic anticancer agents were defined as drugs that can cause heart failure according to the most recent respective European Society of Cardiology guideline.¹⁵ The study complied with the Declaration of Helsinki and was approved by the Charité Ethics Committee, and all patients gave their written informed consent.

ECHOCARDIOGRAPHIC EXAMINATION. A comprehensive 2-dimensional transthoracic echocardiographic examination was conducted and analyzed by 3 well-trained and experienced echocardiographers with standardized operating procedures. Additionally, all LV mass analyses were then validated by 2 independent and experienced echocardiographers who were not aware of the survival status of any participating study subject. We used a Vivid E90 machine (GE Healthcare) for echocardiograms and a Tomtec system for imaging analysis. Cardiac chamber quantification was performed according to the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging.¹³ The modified Simpson method was used to quantify end-systolic and end-diastolic LV volumes and for the biplane

calculation of the LVEF. LV diastolic function was evaluated according to the latest guidelines of the American Society of Echocardiography and the European Association of Cardiovascular Imaging in cancer patients and healthy control subjects (ie, only in subjects with LVEF $\geq 50\%$).³¹ Stroke volume was calculated as the product of the LV outflow tract area and the LV outflow tract time-velocity integral, and cardiac output was calculated by multiplying stroke volume by resting heart rate.³² Speckle-tracking analyses were performed on 2-dimensional gray-scale acquisitions of the apical 4-chamber, 2-chamber, and long-axis views. LV global longitudinal strain was calculated as the mean of all segmental strain values of the apical views.

LEFT VENTRICULAR MASS. LV mass was calculated according to the Devereux formula³³ in all patients and control subjects. LV mass calculation was determined on the basis of linear measurements in 2-dimensional images of the parasternal long-axis views. For validation of the results, we additionally calculated LV mass with a second method: the area-length method³⁴ in the parasternal short-axis view at the level of papillary muscles. This was possible in 259 cancer patients (71 cachectic and 188 noncachectic), 59 healthy control subjects, and 59 heart failure patients. To assess the reproducibility of the 2 measurement methods, a Bland-Altman plot³⁵ was constructed to show limits of agreement. The coefficient of variability (expressed as a percentage) was calculated as the SD of the differences divided by the mean of the parameter under consideration.³⁶ Values of LV mass are provided as absolute values, as well as mass adjusted for height squared³⁷ and mass adjusted for BSA according to the DuBois formula.³⁸


STATISTICAL ANALYSIS. We calculated that we needed to recruit 56 healthy control subjects to detect a difference in LV mass of 10% between healthy control subjects and 300 cancer patients (with 85% power at a 2-sided alpha of 5%), given a common pooled SD of healthy control subjects and cancer patients of LV mass of 32 g.^{39,40} To increase the robustness of the data, we recruited 60 healthy control subjects (20% compared with the cancer group) and similarly chose to include another group of 60 patients with chronic heart failure with reduced ejection fraction for comparison. In addition, for power calculation of the number of repeat echocardiography assessments needed to detect a difference in LV mass of 10% (with 85% power at a 2-sided alpha of 5%), we assumed an SD of repeat LV mass assessments by echocardiography of 38 g.³⁹ On this

basis, we needed 88 cancer patients with repeat echocardiography.


The Kolmogorov-Smirnov test was used for assessment of normal distributions. One-way analysis of variance and the Fisher post hoc test were used as parametric tests, and mean $\pm$ SD are displayed. The Mann-Whitney *U* test and the Kruskal-Wallis test were used as nonparametric tests, and median with IQRs are shown. The analysis of categorical variables was preferably conducted with the chi-square test. Only if 1 cell assignment in the contingency table was smaller than 5, the Fisher exact test was used. For survival analysis in cancer patients, we used a Cox proportional hazards regression model. In univariable and multivariable models for LV mass, sex was used as strata.¹³ The multivariable models were adjusted for routinely assessed oncology care-focused parameters and for known prognostic variables for cancer patients: age (per 1 year); cancer stage (III-IV vs I-II); cancer group (each cancer group vs each other); ECOG performance scale (3-4 vs 0-2); time from diagnosis to study recruitment (per 3 months); cardiotoxic anticancer therapy (yes vs no vs anticancer therapy naive); and hemoglobin (per 1 g/dL). Additionally, these models were adjusted for the following important cardiovascular variables: N-terminal pro-B-type natriuretic peptide (ng/L, per 1 Ln increase); high-sensitivity troponin T (ng/L, per 1 Ln increase); estimated glomerular filtration rate (per 1 mL/min/1.73 m²); and the inflammatory marker C-reactive protein (CRP, mg/L, per 1 Ln increase). Univariable and multivariable HRs, 95% CIs, and *P* values are given. To verify the proportional hazard assumption, which was not found to be violated, the log-minus-log plots were visually inspected. Sex-specific cutpoints¹³ (on the basis of the standardized log-rank test) with the most significant split were chosen to construct Kaplan-Meier cumulative survival plots for illustrative purposes and for further pathophysiologic analyses. The paired Student's *t*-test was used to compare echocardiographic parameters between the first and second echocardiograms. *P* < 0.05 was considered statistically significant in all analyses. The data analysis for this paper was generated using SAS/STAT software version 9.4 (SAS Institute, Inc) and SPSS software version 26.0 (IBM Corp).

RESULTS

STUDY GROUP. Cancer patients, healthy control subjects, and patients with chronic heart failure with reduced ejection fraction (LVEF < 40%) were similar with respect to sex and age. Baseline characteristics

FIGURE 1 LV Mass in Cancer Patients and Control Subjects

Continued on the next page



Continued on the next page

and clinical features of our study patients are displayed in [Table 1](#), and the distribution of cancer types is shown in [Supplemental Table 1](#). Cancer patients had lower values of systolic and diastolic blood pressure, low-density lipoproteins, and hemoglobin in comparison with healthy control subjects. In addition, cachectic cancer patients (n = 87; 29%) had even lower values of systolic and diastolic blood pressure, low-density lipoproteins, and hemoglobin in comparison with noncachectic cancer patients. The frequency of previous cardiotoxic anticancer therapy was similar in cachectic and noncachectic cancer patients. Both cancer subgroups more frequently presented with dyspnea under exertion in comparison with healthy control subjects ([Table 1](#)), but with a frequency similar to that of patients with heart failure.

ECHOCARDIOGRAPHIC EXAMINATION. Cancer patients showed lower LV mass than healthy control subjects (with lower LV internal diameter at end-diastole [LVIDd] and posterior wall thickness at end-diastole [PWD]), and LV mass results remained significant after adjustment for BSA and height squared as calculated with Devereux formula. Cachectic cancer patients presented with lower LV mass, LV mass adjusted for height squared, and LV mass adjusted for BSA, interventricular septal thickness at end-diastole (IVSd), LVIDd, and PWD in comparison with noncachectic cancer patients, healthy control subjects, and heart failure patients ([Figures 1A to 1C](#)). Similar results were observed when the area-length method was applied for absolute and adjusted LV mass calculations ([Supplemental Table 2](#)), with a very high correlation ([Supplemental Figure 1](#)) and a coefficient of variability of 3.4% between both methods ([Supplemental Figure 2](#)).

Compared with findings in healthy control subjects, LV mass was reduced in a similar extent in anticancer therapy-naïve patients, in patients who had received noncardiotoxic therapy before, and in

patients previously treated with known cardiotoxic therapy ([Figure 1D](#)).

As a sensitivity analysis, we excluded all cancer patients and healthy control subjects receiving treatment with any cardiovascular medication and/or with T2DM. In this analysis, LV mass remained reduced in 151 cancer patients vs 41 healthy control subjects ([Supplemental Tables 3 and 4](#)).

Cancer patients presented with lower LVEF, stroke volume, stroke volume index, and cardiac output and with a higher heart rate and pulmonary artery systolic pressure in comparison with healthy control subjects ([Table 2](#)). Considering all cancer patients together, left and right atrium-related measures were not different compared with healthy control subjects ([Table 2](#)). This finding was also seen when patients or control subjects receiving any cardiovascular medication and/or having T2DM were excluded ([Supplemental Table 4](#)).

Cachectic cancer patients, analyzed separately vs noncachectic cancer patients, healthy control subjects, and heart failure patients, showed lower LV, left atrium, left atrial volume index, and right atrium cavity volume ([Table 2](#)). LVEF, global longitudinal strain, septal tissue Doppler velocity (septal e'), tricuspid annular plane systolic excursion, stroke volume, stroke volume index, and cardiac output were lower and heart rate was higher in cachectic cancer patients in comparison with noncachectic cancer patients.

SURVIVAL ANALYSIS. Patients were followed up from baseline to April 2021 (unless they died earlier) for a mean of 16 months (minimum 6 months, maximum 40 months). During follow-up, 149 (50%) patients died (1-year survival, 57%; 95% CI: 51%-63%). LV mass and LV mass adjusted for height squared as calculated with the Devereux formula were independent prognostic markers in multivariable Cox survival analysis ([Table 3](#)), with sex as strata and adjusted for age, cancer stage, cancer entity, ECOG

FIGURE 1 Continued

Box plots and comparisons of (A) absolute left ventricular (LV) mass; (B) left ventricular mass/height²; and (C) left ventricular mass/body surface area (BSA). (A to C) Data for healthy control subjects (n = 60), patients with cancer (n = 300), and patients with heart failure (n = 60). Cancer patients are additionally separated into noncachectic (n = 213) and cachectic (n = 87) categories. Cancer patients had lower absolute and relative (height²-adjusted and BSA-adjusted) left ventricular mass than healthy control subjects or heart failure patients. Cachectic cancer patients had lower left ventricular mass (absolute and relative) than noncachectic cancer patients, healthy control subjects, or heart failure patients. (D) Subgroups of cancer patients who were anticancer therapy naïve (n = 96), had noncardiotoxic anticancer therapy (n = 79), or had cardiotoxic anticancer therapy previously (n = 125) all had lower absolute and relative left ventricular mass compared with healthy control subjects. Left ventricular mass was calculated according to the Devereux formula; cachexia is defined as ≥5% weight loss in 12 months and body mass index <24.0 kg/m²; and body surface area was calculated according to the DuBois formula. Values are mean ± SD.

TABLE 2 Baseline Echocardiographic Parameters

	Healthy Control Subjects (n = 60)	All Cancer Patients (n = 300)	Heart Failure (n = 60)	ANOVA P Value ^a (All Cancer Patients vs Healthy Control Subjects vs Heart Failure)	Cachectic Cancer Patients (n = 87)	Noncachectic Cancer Patients (n = 213)	ANOVA P Value ^b (Cachectic vs Noncachectic Cancer Patients vs Healthy Control Subjects vs Heart Failure Patients)
LV mass, g	203 ± 64	177 ± 47 ^{c,d}	300 ± 71 ^c	<0.001	153 ± 42 ^{c,d,e}	187 ± 45 ^{d,f}	<0.001
LV mass index (LV mass/height ²), g/m ²	68 ± 16	60 ± 14 ^{c,d}	102 ± 23 ^c	<0.001	53 ± 14 ^{c,d,e}	63 ± 13 ^{d,f}	<0.001
LV mass index (LV mass/BSA), g/m ²	106 ± 23	96 ± 20 ^{c,d}	155 ± 34 ^c	<0.001	91 ± 22 ^{c,d,g}	98 ± 19 ^{d,f}	<0.001
IVSd, mm	10.7 ± 1.4	10.5 ± 1.7	10.8 ± 1.8	0.23	9.9 ± 1.7 ^{e,h,i}	10.7 ± 1.6	<0.001
LVIDd, mm	46.9 ± 5.7	44.8 ± 5.3 ^{c,h}	57.8 ± 6.1 ^c	<0.001	42.9 ± 4.5 ^{c,d,e}	45.6 ± 5.5 ^d	<0.001
PWd, mm	9.8 ± 1.2	9.4 ± 1.2 ^{d,f}	10.4 ± 1.5 ^f	<0.001	9.1 ± 1.2 ^{d,g,h}	9.6 ± 1.2 ^d	<0.001
LV end-diastolic apical length, mm	73.8 ± 7.3	73.8 ± 7.9 ^d	83.8 ± 8.0 ^c	<0.001	71.3 ± 8.1 ^{d,e}	74.9 ± 7.5 ^d	<0.001
LV end-diastolic volume, mL	97 ± 28	89 ± 29 ^d	167 ± 59 ^c	<0.001	79 ± 29 ^{d,h,j}	93 ± 28 ^d	<0.001
LV end-diastolic volume index (LVEDV/BSA), mL/m ²	51 ± 11	48 ± 14 ^d	86 ± 28 ^c	<0.001	47 ± 16 ^d	49 ± 13 ^d	<0.001
LA end-systolic volume, mL	49 ± 15	44 ± 15 ^d	81 ± 36 ^c	<0.001	36 ± 12 ^{c,d,e}	47 ± 15 ^d	<0.001
LAVI (LAESV/BSA), mL/m ²	26 ± 6	24 ± 7 ^d	41 ± 18 ^c	<0.001	22 ± 7 ^{d,f,g}	24 ± 7 ^d	<0.001
RA end-systolic volume, mL	36 ± 12	33 ± 13 ^d	54 ± 24 ^c	<0.001	28 ± 10 ^{d,e,h}	35 ± 14 ^d	<0.001
RAVI (RAESV/BSA), mL/m ²	19 ± 6	18 ± 6 ^d	28 ± 12 ^c	<0.001	17 ± 6 ^{d,f}	18 ± 7 ^d	<0.001
LV ejection fraction, %	68 ± 3	64 ± 4 ^{c,d}	31 ± 6 ^c	<0.001	63 ± 5 ^{c,d,e}	65 ± 4 ^{c,d}	<0.001
LV GLS, %	-19.4 ± 3.1	-18.6 ± 3.2 ^d	-12.8 ± 2.4 ^c	<0.001	-17.7 ± 3.1 ^{c,d,e}	-18.9 ± 3.2 ^d	<0.001
Mitral septal e' velocity, cm/s	8.6 ± 1.8	8.2 ± 2.6 ^d	5.8 ± 2.4 ^c	<0.001	7.7 ± 2.6 ^{d,f,g}	8.4 ± 2.6 ^d	<0.001
Mitral lateral e' velocity, cm/s	10.8 ± 2.5	10.4 ± 3.7 ^d	7.4 ± 3.1 ^c	<0.001	10.4 ± 4.4 ^d	10.4 ± 3.4 ^d	<0.001
Mitral E/e' mean	7.8 ± 1.6	8.4 ± 2.6 ^d	14.9 ± 8.1 ^c	<0.001	8.3 ± 2.8 ^d	8.5 ± 2.5 ^d	<0.001
PASP, mm Hg	26 ± 4	29 ± 8 ^{d,h}	35 ± 14 ^c	<0.001	30 ± 8 ^{d,f}	29 ± 8 ^{d,f}	<0.001
Normal diastolic function	60 (100)	282 (94)	N/A	0.052	81 (93)	201 (94)	0.075
TAPSE, mm	25 ± 3	25 ± 4 ^d	19 ± 4 ^c	<0.001	23 ± 4 ^{d,e,h}	25 ± 3 ^d	<0.001
Mitral valve regurgitation				<0.001			<0.001
None/trivial	53 (88)	237 (79) ^d	26 (43) ^c		66 (76) ^d	171 (80) ^d	
Mild	6 (10)	57 (19)	18 (30) ^f		19 (23)	38 (18) ^j	
Moderate	1 (2)	6 (2) ^d	16 (27) ^f		2 (2) ^d	4 (2) ^d	
Tricuspid valve regurgitation				<0.001			<0.001
None/trivial	48 (80)	225 (75) ^d	31 (52) ^h		59 (68)	166 (78) ^d	
Mild	12 (20)	72 (24)	18 (30)		27 (33)	45 (21)	
Moderate	0 (0)	3 (1) ^d	11 (18) ^c		1 (1) ^d	2 (1) ^d	
Stroke volume, mL	63 ± 14	53 ± 14 ^{c,d}	41 ± 13 ^c	<0.001	43 ± 10 ^{c,e}	56 ± 13 ^c	<0.001
Stroke volume index (SV/BSA), mL/m ²	33 ± 5	29 ± 7 ^{c,d}	22 ± 7 ^c	<0.001	26 ± 7 ^{c,e,k}	30 ± 7 ^{c,d}	<0.001
Heart rate during echocardiography, beats/min	65 ± 10	76 ± 16 ^c	74 ± 15 ^c	<0.001	81 ± 17 ^{c,e,k}	73 ± 14 ^c	<0.001
Cardiac output, L/min	4.06 ± 1.05	3.92 ± 1.16 ^{c,d}	3.08 ± 1.13 ^c	<0.001	3.50 ± 0.93 ^{e,h,i,j}	4.08 ± 1.19 ^d	<0.001

Values are mean ± SD or n (%). P values for nominal variables refer to all comparison groups. ^aANOVA P value/chi-square test for comparisons among cancer patients, healthy control subjects, and heart failure patients. ^bANOVA P value/ chi-square test for comparisons among cachectic cancer patients, noncachectic cancer patients, healthy control subjects, and heart failure patients. ^cP <0.001 vs control subjects. ^dP <0.001 vs heart failure. ^eP <0.001 vs noncachectic cancer patients. ^fP <0.05 vs control subjects. ^gP <0.05 vs noncachectic cancer patients. ^hP <0.01 vs control subjects. ⁱP <0.05 vs heart failure. ^jP <0.01 vs noncachectic cancer patients. ^kP <0.01 vs heart failure.

ANOVA = analysis of variance; BSA = body surface area according to the DuBois formula; E/e' = early diastolic filling velocity (E) over mitral annulus early diastolic tissue velocity (e'); GLS = global longitudinal strain; IVSd = interventricular septal thickness at end-diastole; LA = left atrium; LAEDV = left atrial end-diastolic volume; LAESV = left atrial end-systolic volume; LAVI = left atrium volume index; LV = left ventricular; LVIDd = left ventricular internal diameter at end-diastole; PASP = pulmonary artery systolic pressure; PWd = posterior wall thickness at end-diastole; RA = right atrium; RAVI = right atrium volume index; TAPSE = tricuspid annular plane systolic excursion.

performance scale, time from diagnosis to study recruitment, cardiotoxic anticancer therapy, and hemoglobin. LV mass adjusted for BSA was not a predictor of all-cause mortality. Similar results were found when the area-length method was used (Supplemental Table 5). The Kaplan-Meier curves, on the basis of the best sex-specific cutpoints for absolute and height squared -adjusted LV mass values (absolute: ≥151 g/≥210 g; height squared

-adjusted: ≥61 g/≥57g for female/male subjects), underlines the survival benefit of patients with higher LV mass (Figures 2A and 2B).

In additional analyses, 6-minute walking distance, stair-climbing power, maximum handgrip strength, ECOG performance scale, and Karnofsky performance status were significantly impaired in patients with prognostically relevant cardiac wasting (Table 4). Furthermore, we analyzed the prognostic value of left

TABLE 3 Cox Regression Analyses for All-Cause Mortality in all 300 Cancer Patients				
	Univariable Analysis		Multivariable Analysis	
	HR (95% CI)	P Value	HR (95% CI)	P Value
LV mass – Devereux formula (per 20 g less)	1.12 (1.03-1.22)	0.010 ^a	1.11 (1.00-1.22)	0.045 ^b
LV mass index (LV mass/height ²) (per 20 g/m ² less)	1.34 (1.04-1.72)	0.025 ^a	1.46 (1.10-1.94)	0.009 ^b
LV mass index (LV mass/BSA) (per 20 g/m ² less)	1.09 (0.91-1.31)	0.34 ^a	—	—
Age (per 1 y)	1.02 (1.01-1.04)	<0.001	1.01 (1.00-1.03) ^c	0.120
Sex (male vs female)	1.02 (0.74-1.40)	0.93	—	—
Cancer stage (III-IV vs I-II)	4.87 (2.56-9.27)	<0.001	1.74 (0.86-3.50) ^c	0.122
Cancer entity groups	—	<0.001	—	—
ECOG (per 1 grade increase)	1.91 (1.62-2.25)	<0.001	1.47 (1.19-1.81) ^c	<0.001
Time from diagnosis to recruitment (per 3 months)	1.01 (1.00-1.02)	0.002	1.00 (0.99-1.01) ^c	0.755
Cardiotoxic anticancer therapy (yes vs no vs anticancer therapy naïve) ^d	—	<0.001	—	—
Hemoglobin (per 1 g/dL)	0.91 (0.85-0.98)	0.013	1.01 (0.91-1.12) ^c	0.800
Ln NT-proBNP, ng/L (per 1 Ln increase)	1.26 (1.11-1.43)	<0.001	1.15 (0.96-1.37) ^c	0.130
Ln hs troponin T, ng/L (per 1 Ln increase)	1.63 (1.35- 1.97)	<0.001	1.26 (0.98-1.61) ^c	0.071
eGFR (per 1 mL/min/1.73 m ²)	0.99 (0.98-1.00)	0.013	1.01 (1.00-1.02) ^c	0.089
Ln CRP, mg/L (per 1 Ln increase)	1.40 (1.25-1.55)	<0.001	1.19 (1.04-1.36) ^c	0.012

^aSex as strata. ^bSex as strata and adjusted for age (per 1 year), cancer stage (III-IV vs I-II), cancer entity groups, ECOG (1-4), time from diagnosis to recruitment (per 3 months), cardiotoxic anticancer therapy (yes vs no vs anticancer therapy naïve), hemoglobin (per 1 g/dL), log-transformed NT-proBNP, log-transformed hs troponin T, eGFR, and log-transformed CRP. ^cData provided for the multivariable analysis, including LV mass – Devereux formula (additional data for LV mass/height² shown in Supplemental Table 9). ^dSignificant subgroup differences: cardiotoxic anticancer therapy vs anticancer therapy naïve: HR: 0.36 (95% CI: 0.22-0.59); *P* < 0.001; noncardiotoxic anticancer therapy vs anticancer therapy naïve: HR: 0.38 (95% CI: 0.22-0.64); *P* < 0.001; multivariable: cardiotoxic anticancer therapy vs anticancer therapy naïve: HR: 0.54 (95% CI: 0.33-0.88); *P* = 0.013; noncardiotoxic anticancer therapy vs anticancer therapy naïve: HR: 0.86 (95% CI: 0.50-1.48); *P* = 0.589.

LV = left ventricular; other abbreviations as in Table 1.

atrial and right atrial volumes (absolute and adjusted for height squared , as well as for BSA). In univariable analyses, patients in the highest tertile of left and right atrial dimensions had the best prognosis, but in multivariable analyses, none of these findings were significant (Supplemental Table 6).



ECHOCARDIOGRAPHIC FOLLOW-UP. In total, 90 cancer patients received a second echocardiographic examination after 122 ± 71 days (baseline characteristics in Supplemental Table 7). LV mass was found to be reduced by 9.3% ± 1.4% in comparison with the first assessment (first assessment, 187 ± 48 g vs second assessment, 169 ± 48 g; *P* < 0.001) (Figure 3). Cancer patients with definite LV mass reduction (change ≥10.0%; average reduction of LV mass 20.3% ± 1.1%; n = 40; 44% of patients) showed lower values of IVSd, LVIDd, PWD, and stroke volume but higher resting heart rates at follow-up (Supplemental Table 8). In contrast, patients without LV mass reduction (change <5.0%; average increase of LV mass 3.5% ± 1.7%; n = 31; 34% of patients) had increased LVIDd and stroke volume and unchanged resting heart rates at follow-up. When patients with LV mass reduction ≥10% vs <5% at follow-up were compared for baseline results, a measure of inflammatory status—interleukin (IL)-6—was found to be significantly increased, and levels of CRP were nominally increased (Supplemental Table 7). Of note,

CRP, IL-1β, IL-6, IL-10, and tumor necrosis factor (TNF) were increased in cancer patients in general. IL-1β and IL-6 values were higher in cachectic vs noncachectic cancer patients (Table 1). IL-1β, IL-10, and TNF values were not found to be (more) increased in patients with subsequent LV mass reduction ≥10% vs <5% (Supplemental Table 7). The frequency of cardiotoxic anticancer therapy was similar in cancer patients with LV mass reduction ≥10% vs <5% (Supplemental Table 7).

DISCUSSION

In this study, we have shown that patients with mostly advanced-stage active cancer presented with a lower absolute and indexed LV mass in comparison with healthy control subjects and patients with chronic heart failure. Compared with healthy control subjects, LV mass was reduced in a similar extent in anticancer therapy-naïve patients, in patients who had received noncardiotoxic anticancer therapy previously, and in patients who had previously received known cardiotoxic anticancer therapy. LV mass, stroke volume, blood pressure, and cardiac output were particularly low in cancer patients with whole body cachexia. Reduced LV mass, in absolute terms and adjusted for height squared, was an independent marker of poor survival in patients with cancer. However, when LV mass was adjusted for BSA, the

FIGURE 2 Survival in Cancer Patients According to Sex-Specific LV Mass Cutoffs



The Kaplan-Meier curves are based on the best sex-specific cutpoints for (A) absolute left ventricular (LV) mass values (ie, <151 g/<210 g for female/male subjects) and (B) height²-adjusted left ventricular mass values (ie, <61 g/m²/<57 g/m² for female/male subjects). The results shown underline the increased mortality observed in patients with lower left ventricular mass. Left ventricular mass was calculated according to the Devereux formula.

TABLE 4 Patient-Reported Outcomes and Functional Testing in Patients With and Without Prognostically Relevant Cardiac Wasting

	LV Mass Index (Mass/Height ²) <61 g/m ² in Women, <57 g/m ² in Men (n = 154)	LV Mass Index (Mass/Height ²) ≥61 g/m ² in Women, ≥57 g/m ² in Men (n = 146)	P Value
ECOG performance scale, points	1.8 ± 1.1	1.6 ± 1.1	0.033
Karnofsky Index, %	72 ± 19	77 ± 19	0.038
EQ-5D-5L score (n = 123 vs 113)	0.755 (0.427-0.909)	0.830 (0.501-0.959)	0.066
Visual Analogue Scale for appetite, mm	50 (29-75)	63 (31-84)	0.11
Visual Analogue Scale for pain, mm	11 (0-40)	10 (0-40)	0.53
Mini Nutritional Assessment, points	19.8 ± 4.4	21.3 ± 4.3	0.009
Maximum handgrip strength, newton	266 ± 122	320 ± 157	0.001
4-m gait speed, ms	1.08 ± 0.38	1.14 ± 0.37	0.15
Stair-climbing power, W (n = 62 vs 68)	294 (238-413)	432 (330-523)	<0.001
6-min walking distance, m (n = 61 vs 62)	418 ± 94	455 ± 99	0.034

Values are mean ± SD or median (IQR). P values for nominal variables refer to both comparison groups.
ECOG = Eastern Cooperative Oncology Group; LV = left ventricular.

prognostic significance of this parameter was masked. Interestingly, 6-minute walking distance, stair-climbing power, maximum handgrip strength, ECOG performance scale, and Karnofsky performance status were significantly impaired in patients with prognostically relevant cardiac wasting (**Central Illustration**). Loss of LV mass over time was associated with a reduction of stroke volume and an increase in resting heart rate. We suggest that these findings represent *cardiac wasting-associated cardiomyopathy* in cancer patients.


Cardiac wasting is known to occur at later stages in the progression of whole body cachexia in chronic illness.⁴¹ Small hearts (with regard to mass and volume) have also been observed in patients with severe malnutrition (eg, in kwashiorkor⁴² and in anorexia nervosa^{43,44}). In heart failure, cardiac wasting is also known to occur.⁴⁵ Studies in preclinical models of cancer cachexia have shown that cardiac wasting is associated with increased proteolysis, fibrosis, and impaired cardiomyocyte ultrastructure.⁷ It can be caused by different intrinsic factors such as oncometabolites, inflammatory cytokines, oxidative stress, and metabolic stress.⁴ Biomarkers that have been linked to cardiac wasting in such models include inflammatory cytokines, the transforming growth factor- β family, and nuclear factor- κ B.⁵ In the past, extensive research also focused on cellular oxidative stress and the increased inflammatory response in the cardiac milieu as a consequence of cardiotoxic anticancer drugs.¹⁵ Therefore, we included cancer patients with or without previous cardiotoxic or noncardiotoxic anticancer therapy to investigate these possible effects in humans.

In humans, first data on cardiac wasting in cancer patients came from 2 retrospective studies reporting

data on 6 and 177 autopsy reports, respectively.^{9,10} In the first study, the investigators found fibrotic changes in the cardiac muscle of cancer patients.⁹ The second report suggested that patients with cancer-induced cachexia had a 19% lower LV mass compared with cancer patients without cachexia.¹⁰ In addition, Kazemi-Bajestani et al¹¹ reported on 50 cancer patients with a focus on only 1 tumor entity (non-small cell lung cancer) and investigating patients before and after chemotherapy administration. These investigators documented the presence of cardiac wasting in patients with non-small cell lung cancer (9% during 4 months of follow-up) to a similar degree as seen here in a much larger cohort with different cancer entities. Cardiac wasting was found to be associated with changes in cardiac function as indicated by altered global longitudinal strain. These investigators did not assess the functional status of the patients with non-small cell lung cancer, and the study was not powered for prognostic assessments.

Our results, on the basis of 300 cancer patients without significant cardiovascular disease at baseline and different cancer types, demonstrate the presence of cardiac wasting, irrespective of the anticancer therapy status (naïve, noncardiotoxic, cardiotoxic therapy). In addition, lower LV mass was associated with poor functional status, as well as an increased risk of all-cause mortality. Importantly, we show that in cancer patients, absolute LV mass and LV mass adjusted for height squared predict all-cause mortality, whereas LV mass adjusted for BSA does not.

In our analysis, the presence of reduced LV mass was accompanied by morphologic and functional cardiac abnormalities (ie, smaller cardiac cavities, thinner myocardial walls, and reduced systolic function) as a reflection of the underlying (cardiac)



wasting processes in cancer. Cancer cachexia is well known to be associated with an increased inflammatory response.⁴⁶ Cancer patients with vs without cardiac wasting identified in our echocardiographic follow-up had higher baseline levels of circulating IL-6 and nominally increased CRP (whereas IL-1 β and TNF were not found to be increased). Moreover, patients with cardiac wasting at follow-up had reduced stroke volume and also increased resting heart rate. The latter could be considered a compensatory mechanism in this *cardiac wasting-associated cardiomyopathy*. The presence of anemia, low blood pressure, and raised heart rate, as well as mechanistic considerations of the changed physics of the heart as a pump when cardiac wasting develops,⁴ may suggest the presence of a heart failure-like syndrome. Why these developments in *cardiac wasting-associated cardiomyopathy* do not lead to a compensatory increase in LV volumes we do not know; however, the lack of “material” (given the ongoing wasting processes) may simply put a limit to that pathophysiologic option. Of interest, the situation appears to be different in patients with chronic heart failure with reduced ejection fraction. They have the lowest blood pressure, the highest natriuretic peptide levels, and still by far the highest LV mass.

It is noteworthy that patients with vs without cardiac wasting during follow-up did not show whole

body cachexia at baseline more often. Hence, whole body cachexia and cardiac wasting may be occurring one after another in many cancer patients, but not in all. One also needs to consider whether the cardiac wasting (as seen in our study) is related to the general process of (skeletal) muscle wasting (ie, sarcopenia). The concept of sarcopenia was originally developed for muscle wasting in response to aging.⁴⁷ The concept is now also used for muscle wasting in any chronic illness, and then it is referred to as secondary (disease-mediated) sarcopenia vs primary (aging-associated) sarcopenia.⁴⁸ Sarcopenia is present in heart failure already when body weight overall is still stable.⁴⁹ This is the same in chronic cancer, where sarcopenia has even been described in obese cancer patients.⁵⁰ Hence, we hypothesize that the pathophysiology of cardiac wasting in cancer is independent of that of skeletal muscle wasting in cancer.


As seen in our study, the wasting processes affect the whole heart in some cancer patients. This is particularly evident in patients with cancer cachexia for the left ventricle and both atria (Table 2). In cancer patients without cachexia, however, LV mass is seen reduced, but LV volume is not changed, and left and right atrial dimensions are not reduced (Table 2). Whether the isolated observation of a somewhat lower LV mass already represents a “shrunk heart” in noncachectic patients could be debated. In

CENTRAL ILLUSTRATION Cardiac Wasting in Patients With Advanced Cancer


A Patients With Prognostically Relevant Cardiac Wasting

Maximum handgrip strength	↓
Stair-climbing power	↓
6-minute walking distance	↓
Mini Nutritional Assessment	↓
ECOG performance scale	↑
Karnofsky Index	↓


B LV Mass in Healthy Controls and Cancer Patients



C Change in LV Mass Over 4 Months (n = 90)



D Kaplan-Meier Curves for Prognostically Relevant Cardiac Wasting According to LV Mass (n = 300)



Lena A, et al. J Am Coll Cardiol. 2023;81(16):1569-1586.

(A) Patients with prognostically relevant cardiac wasting have impaired functional status. (B) Box plots and comparisons of left ventricular mass are shown. Cancer patients in general and particularly cachectic cancer patients have lower left ventricular mass than healthy control subjects. (C) In total, 90 cancer patients received a second echocardiographic examination after 122 ± 71 days. Left ventricular mass was found to be reduced by $9.3\% \pm 1.4\%$ in comparison with the first assessment (first assessment, 187 ± 48 g vs second assessment, 169 ± 48 g; $P < 0.001$). A definitive left ventricular mass reduction ($\geq 10.0\%$) was seen in 44% of cancer patients. (D) Kaplan-Meier curves for overall survival on the basis of the best (sex-specific) cutpoints for mortality-predictive absolute left ventricular mass (ie, <151 g/ <210 g in women/men),—showing the increased mortality observed in patients with lower left ventricular mass. Left ventricular mass calculated according to the Devereux formula. ECOG = Eastern Cooperative Oncology Group.

cachectic patients, when LV mass wasting is very significant and LV and atrial volumes are decreased, a “shrinking of the heart” (ie, cardiac wasting) can be considered present in most of these patients. We suggest that possible increases in LV wall stress are the consequence of these wasting processes, not their cause.

There may be 2 reasons that cardiac wasting in cancer patients has not been adequately described before and has received little clinical and research attention so far. First, it is likely that cardiac wasting is a late onset phenomenon in cancer patients.⁴ In chronic heart failure, 2 studies, using echocardiography and magnetic resonance imaging, respectively,

showed that body cachexia predates cardiac wasting, which is a very late phenomenon in heart failure patients.^{51,52} If this is the same in cancer, cardiac wasting may develop particularly strongly once whole body cachexia is present because the heart may initially be better protected from wasting than skeletal muscle or fat tissue. Second, according to the American Society of Echocardiography and the European Association of Cardiovascular Imaging, most large population studies have reported LV mass indexed only for BSA, which takes into account height and weight of the patient.¹³ When cancer patients lose body weight overall (which is often the case in advanced cancer), BSA decreases as well, and in turn

the ratio of LV mass and BSA will increase. Therefore, adjusting LV mass for BSA may mask absolute declines in LV mass.

Overall, this explains why LV mass in absolute terms and LV mass/height² were independent prognostic markers, whereas LV mass/BSA was not. We therefore suggest not adjusting LV mass measurements in cancer patients for BSA, but preferably for height squared or to report only unadjusted data. We chose to raise height by the power of 2.0, as proposed by Lauer et al in 1994,³⁷ when investigating methods of “best” adjustment of LV mass in people free of cardiovascular disease. As we did here, Lauer et al³⁷ proposed adjusting LV mass not by BSA, but by a weight independent variable (ie, height to a non-integer power). Their model was developed in 1,101 patients with a logarithmic regression model trying to reduce differences between male and female patients and to be independent of obesity. The best fit results for which adjustments to use were (in their study) for women 1.91 and for men 2.12. In a pooled analysis, Lauer et al³⁷ found 1.97 to be the best noninteger to use. We selected adjusting by the power of 2.0 to make it practical for anyone to redo what we have done.

So far, very few preclinical studies investigating possible therapies for cancer associated cachexia or even cardiac wasting-associated cardiomyopathy exist. Our group (Springer et al⁹) has shown that bisoprolol (beta-blocker) or spironolactone (aldosterone receptor antagonist) could attenuate cardiac wasting in a rat model of liver cancer with severe cachexia (and cardiac wasting). The same group also reported that espidolol was able to attenuate cardiac wasting in this model.⁵³ Espindolol is now in development for cancer cachexia. In the ACT-ONE trial, espidolol was tested in cancer patients with cachexia caused by non-small cell lung or colorectal cancer, and it was associated with an increase in handgrip strength, body weight, and lean body mass.²⁷ The weight gain seen amounted to 4 kg in 4 months, which is much higher than is typical for racemic beta-blockers (typically 1-1.5 kg weight gain in 1 year in patients with heart failure).⁵⁴

STUDY LIMITATIONS. Our study focused on hospitalized patients with mostly advanced cancer. These patients tend to have a globally reduced performance status and a reduced 1-year-overall-survival.⁴ Furthermore, patients had several different cancer entities that represented a cross section of patients treated in a clinical oncology department, and we suggest that this can be considered a strength as well as a weakness of this study. Cancer stages may not be

comparable among cancer entities, but we also used clinical status markers (ECOG) for adjustment. The echocardiographic follow-ups were performed in a variable time frame (mostly within the first 2-7 months [range 1-12 months]). Clinically, a fully unified approach was not possible. Follow-ups were possible only in patients who were alive, and therefore some degree of a survivorship bias may be present. Patients with T2DM without cardiovascular complications and controlled arterial hypertension were not excluded. These diseases are known to be associated with LV hypertrophy and should not have negatively influenced the key results and, if anything, could even lead to some degree of underestimation of the frequency of cardiac wasting in these patients.^{55,56} In future studies, it would also be desirable to assess the presence of increased myocardial wall stress in cancer patients with cardiac wasting-associated cardiomyopathy.⁴ In addition, other factors such as prolonged immobility, malnutrition, and multiorgan dysfunction may have an impact on cardiac wasting.⁵ Future studies could extend this research to patients with early-stage cancer and further investigate the role of physical activity and nutrition on cardiac wasting. Given that the rate of autopsies in cancer patients is generally very low, and the clinical presentation is often complex, and because patients often die at home or in hospice care, we used all-cause mortality for this study.⁵⁷ Nonetheless, further investigations on the specific cause of death in cancer patients are needed.

CONCLUSIONS

Our study indicates that wasting of the left ventricle of the heart frequently occurs in patients with mostly advanced cancer. This cardiac wasting is associated with poor functional status of patients, as well as with increased all-cause mortality. We suggest that LV mass adjustment for BSA can mask this information, and adjustment for height squared appears more appropriate. We also suggest that these findings represent cardiac wasting-associated cardiomyopathy in cancer.

ACKNOWLEDGMENTS The authors thank the patients and staff who were involved in this study.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This study was partly funded by the German Centre for Cardiovascular Research through research support to Dr Hadzibegovic, Dr S. Anker, and Dr M. Anker. Dr Wilkenshoff is supported by a Clinical Fellowship Grant from the Berlin Institute of Health; and has received speaker fees and/or contributions to congresses from Abbott, AstraZeneca, Bayer, Berlin Chemie, Bristol Myers Squibb, GE Healthcare, Pfizer, Philips, and Servier, all outside the submitted work. Dr Zeller

has received support from the German Centre for Cardiovascular Research (FKZ 81Z1710101 and FKZ 81Z0710102). Dr Karakas is supported by a Clinician Scientist Professorship Grant from the Else Kroener-Fresenius-Foundation; and has received personal fees and grant support from Daiichi-Sankyo, Adrenomed, Sphingotec, and Vifor Pharma, all outside the submitted work. Dr Keller has served on advisory boards for Roche, Janssen-Cilag, Celgene, Takeda, Bristol Myers Squibb, Gilead, Hexal, Pfizer, AstraZeneca, and Pentixapharm; has received clinical research support from Janssen-Cilag, Novartis, Takeda, Bristol Myers Squibb, Roche, and Pfizer; and has received travel support from Roche, Bristol Myers Squibb, Gilead, Takeda, Janssen-Cilag, and Celgene. Dr Bullinger has received honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi-Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche, Sanofi, and Seattle Genetics; and has received research support from Bayer and Jazz Pharmaceuticals. Dr Lyon has received support from the Fondation Leducq Transatlantic Network of Excellence in Cardio-Oncology; and has received speaker, advisory board, or consulting fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssen-Cilag, Clinigen, Eli Lilly, Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA Health, and Heartfelt Technologies. Dr Lüscher has received educational and research grants from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Sanofi, Servier, and Vifor; and has received consulting honoraria from Amgen, COR2ED, Daiichi-Sankyo, and Pfizer, outside this work. Dr Totzeck has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, and Daiichi-Sankyo, all unrelated to this work. Dr Rassaf has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiichi-Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all unrelated to this work. Dr Burkhoff has received consulting fees from AquaPass, Axon Medical, BioMind, CardioDyme, Corvia Medical, IMPULSE Dynamics, Orchestra Biomedical, PVLoops, and Zoll, all unrelated to the present work. Dr Mehra has received payments from Abbott to his institution for consulting; has received consulting fees from Janssen, Mesoblast, Broadview Ventures, Natera, Paragonix, Moderna, and Baim Institute for Clinical Research; and serves on the advisory board of NuPulseCV, Leviticus, Transmedics, and FineHeart. Dr Bax has received unrestricted research grants to his institution from Edwards Lifesciences, Abbott, Medtronic, Biotronik, and Boston Scientific; and has received personal speaker fees from Abbott and Edwards Lifesciences. Dr Butler has received personal fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr S. Anker has received grants and personal fees from Vifor and Abbott Vascular; and has received personal fees for consulting, trial committee work, and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Edwards Lifesciences, Faraday, Impulse Dynamics, Janssen, Novartis, Occlutech,

Pfizer, Respicardia, Servier, Vectorious, and V-Wave, all outside the submitted work; and is named co-inventor of 2 patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but does not benefit personally from the related issued patents. Dr Packer has served as a consultant for AbbVie, Actavis, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Eli Lilly, Moderna, Novartis, Reata, Relypsa, and Salamandra. Dr Coats has received honoraria and/or speaker fees from AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, and Viatrix. Dr von Haehling has received consulting fees and/or honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor; and has received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Innovative Medicines Initiative, and the German Centre for Cardiovascular Research. Dr Landmesser has received institutional research grants from Amgen, Bayer, and Novartis; and has received speaker or consulting honoraria from AstraZeneca, Bayer, Boehringer, Amgen, Sanofi, Novartis, and Novo Nordisk. Dr M. Anker has received personal fees from Servier, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Markus S. Anker, German Heart Center Charité - Campus Benjamin Franklin, Charité - University Medicine Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. E-mail: markus.anker@charite.de.

PERSPECTIVE

COMPETENCY IN PATIENT CARE AND

PROCEDURAL SKILLS: Cardiac wasting is common among patients with advanced cancer, and it is associated with cachexia, poor functional status, and an increased risk of death. Adjustment of LV mass for height squared may be more appropriate than adjustment for BSA in this situation.

TRANSLATIONAL OUTLOOK: Further research is needed to understand the pathophysiology and clinical consequences of cardiac wasting in patients with advanced cancer and develop potential therapeutic interventions.

REFERENCES

1. Sun L, Quan XQ, Yu S. An epidemiological survey of cachexia in advanced cancer patients. *Nutr Cancer*. 2015;67:1056-1062.
2. Vagnildhaug OM, Balstad TR, Almberg SS, et al. A cross-sectional study examining the prevalence of cachexia. *Support Care Cancer*. 2018;26:1871-1880.
3. Peixoto da Silva S, Santos JMO, Costa E Silva MP, et al. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia, and asthenia. *J Cachexia Sarcopenia Muscle*. 2020;11:619-635.
4. Anker MS, Sanz AP, Zamorano JL, et al. Advanced cancer is also a heart failure syndrome: a hypothesis. *Eur J Heart Fail*. 2021;23(1):140-144.
5. Argilés JM, Stemmler B, López-Soriano FJ, Busquets S. Inter-tissue communication in cancer cachexia. *Nat Rev Endocrinol*. 2018;15:9-20.
6. Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? *J Cachexia Sarcopenia Muscle*. 2020;11:1413-1428.

7. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. *Int J Oncol*. 2010;37:347–353.
8. Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. *Cancer Res*. 2011;71:1710–1720.
9. Springer J, Tschirner A, Haghighi A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. *Eur Heart J*. 2014;35:932–941.
10. Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cardiac cachexia. *ESC Heart Fail*. 2017;4:458–467.
11. Kazemi-Bajestani SMR, Becher H, Butts C, et al. Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. *J Cachexia Sarcopenia Muscle*. 2019;10:1070–1082.
12. Anker MS, von Haehling S, et al. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer. *Eur J Heart Fail*. 2021;23:145–153.
13. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1–39e14.
14. Marçôa R, Rodrigues DM, Dias M, et al. Iassification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011. *COPD*. 2018;15:21–26.
15. Authors/Task Force Members, McDonagh TA, Metra M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2022;24:4–131.
16. Oken MM, Creech RE, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5:649–655.
17. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. *Evaluation of Chemotherapeutic Agents*. Columbia University Press; 1949:196.
18. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20:1727–1736.
19. Blauwhoff-Buskermolen S, Ruijgrok C, Ostelo RW, et al. The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. *Support Care Cancer*. 2016;24:661–666.
20. Huskisson EC. Measurement of pain. *Lancet*. 1974;2:1127–1131.
21. Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. *Nutrition*. 1999;15:116–122.
22. Roberts HC, Denison HJ, Martin HJ, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing*. 2011;40:423–429.
23. Kon SS, Patel MS, Canavan JL, et al. Reliability and validity of 4-metre gait speed in COPD. *Eur Respir J*. 2013;42:333–340.
24. Bean JF, Kiely DK, LaRose S, Alian J, Frontera WR. Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults? *Arch Phys Med Rehabil*. 2007;88:604–609.
25. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166:111–117.
26. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cardiac cachexia: an international consensus. *Lancet Oncol*. 2011;12:489–495.
27. Coats AJS, Ho GF, Prabhaskar K, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV NSCLC or CR. *J Cachexia Sarcopenia Muscle*. 2016;7:355–365.
28. Bertero L, Massa F, Metovic J, et al. Eighth edition of the UICC classification of malignant tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? *Virchows Arch*. 2018;472:519–531.
29. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. *Cancer Res*. 1971;31:1860–1861.
30. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer*. 1975;36:842–854.
31. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of LV diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17:1321–1360.
32. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2002;15:167–184.
33. Devereux RB, Reichek N. Echocardiographic determination of LV mass in man. Anatomic validation of the method. *Circulation*. 1977;55:613–618.
34. Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB. Two-dimensional echocardiographic calculation of LV mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. *J Am Soc Echocardiogr*. 1996;9:119–128.
35. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet*. 1986;1:307–310.
36. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol*. 2002;90:29–34.
37. Lauer MS, Anderson KM, Larson MG, Levy D. A new method for indexing LV mass for differences in body size. *Am J Cardiol*. 1994;74:487–491.
38. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med (Chic)*. 1916;17:863–871.
39. Meléndez GC, Sukphruth B, D'Agostino RB Jr, et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. *Am J Cardiol*. 2017;119:1637–1642.
40. Heckbert SR, Post W, Pearson GD, et al. Traditional cardiovascular risk factors in relation to LV mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. *J Am Coll Cardiol*. 2006;48:2285–2292.
41. Heymsfield SB, Bethel RA, Ansley JD, Gibbs DM, Felner JM, Nutter DO. Cardiac abnormalities in cachectic patients before and during nutritional repletion. *Am Heart J*. 1978;95:584–594.
42. Webb JG, Kiess MC, Chan-Yan CC. Malnutrition and the heart. *CMAJ*. 1986;135:753–758.
43. Hanachi M, Pleple A, Barry C, et al. Echocardiographic abnormalities in 124 severely malnourished adult anorexia nervosa patients: frequency and relationship with body composition and biological features. *J Eat Disord*. 2020;8:66.
44. Scheggi V, Castellini G, Vanni F, et al. Echocardiographic abnormalities in adults with anorexia nervosa. *Am J Cardiol*. 2022;175:152–157.
45. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. *Nat Rev Cardiol*. 2017;14:323–341.
46. Palus S, Springer J. Biomarkers for cancer cachexia: where do we stand? *J Cachexia Sarcopenia Muscle*. 2020;11:1388–1389.
47. Evans WJ. What is sarcopenia? *J Gerontol A Biol Sci Med Sci*. 1995;50(spec no):5–8.
48. Bauer J, Morley JE, Schols AMWJ, et al. Sarcopenia: a time for action. *J Cachexia Sarcopenia Muscle*. 2019;10:956–961.

49. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. *Eur Heart J*. 1999;20:683–693.
50. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. *Ann Oncol*. 2018;29(suppl 2):iii–ii9.
51. Florea VG, Henein MY, Rauchhaus M, et al. The cardiac component of cardiac cachexia. *Am Heart J*. 2002;144:45–50.
52. Florea VG, Moon J, Pennell DJ, Doehner W, Coats AJ, Anker SD. Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. *Int J Cardiol*. 2004;97:15–20.
53. Pötsch MS, Ishida J, Palus S, et al. MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. *J Cachexia Sarcopenia Muscle*. 2020;11:594–605.
54. Clark AL, Coats AJS, et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe CHF. *J Cachexia Sarcopenia Muscle*. 2017;8:549–556.
55. Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. *Am J Cardiol*. 2008;101:1787–1791.
56. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of Hypertension. Prevalence of left ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. *J Hum Hypertens*. 2012;26:343–349.
57. Bieri U, Moch H, Dehler S, Korol D, Rohrmann S. Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: a longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich. *Virchows Arch*. 2015;466:637–643.

KEY WORDS cancer, cardiac wasting-associated cardiomyopathy, cardiology, echocardiography, left ventricular mass

APPENDIX For supplemental tables and figures, please see the online version of this paper.